Ultimately, the top‐ranked targets, such as AKT1, TNF, IL‐6, vascular endothelial growth factor A (VEGFA), and IL‐1β, were found as the major targets of TY in the treatment of RA. This evidence concerns the gene IL1B and rheumatoid arthritis.